Langley, Canada Clinical Trials
A listing of Langley, Canada clinical trials actively recruiting patients volunteers.
Found 20 clinical trials
Sickle Cell Disease Study: Own Your Health, Share Your Story with PicnicHealth
Get all of your medical records in one secure account and contribute to important real-world Sickle Cell research with PicnicHealth. If you have Sickle Cell, you get $50 for signing up and a free lifetime access to your medical records. Visit this link to learn more and sign up. …
- 11 views
- 04 Aug, 2022
- 1 location
- Online study
Caregiver-Provided Life Review for Persons with Dementia
This study, Caregiver-Provided Life Review (C-PLR) is created based on Life Review therapy. It is for persons living with early-stage dementia along with mild depressive symptoms who are 65 years or older, community-dwellers or the residents of senior housing, independent or assisted living facilities conducted by their family members (18 …
- 547 views
- 09 Aug, 2022
- 1 location
- Online study
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period.
- 13 views
- 14 Jul, 2022
- +21 other locations
INCB 18424-303: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE-AD1)
A Phase 3, randomized (2:2:1), double-blind, 8-week vehicle control efficacy and safety study of ruxolitinib followed by a randomized, double-blind, 44-week long term safety (LTS) extension period. In the LTS period, participants initially randomized to vehicle will receive either ruxolitinib 0.75% or 1.5% cream. All participants will have follow-up assessments …
- 582 views
- 10 May, 2022
- +18 other locations
Integument-2 study
We are currently recruiting pediatric and adult patients with mild to moderate atopic dermatitis (eczema) for a study that investigates the safety and efficacy of the ARQ-151 cream.
- 68 views
- 07 Jul, 2022
- +62 other locations
Objective, Passive Assessment of LRRK2 Carriers (OPAL)
This study is currently only open to active participants in the University of Rochester’s VALOR-PD study. The goal of this project is to identify objective, sensitive, and convenient measures for assessing early signs of Parkinson's disease in an at-risk population at home. We will do so by using a wireless …
- 8 views
- 12 May, 2022
- 1 location
- Online study
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) (DELTA 2)
This is a 16-week study in adult participants with chronic hand eczema (CHE). The participants will visit the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and quality of life. The purpose is to assess how delgocitinib cream works …
- 10 views
- 14 Jun, 2022
- +46 other locations
Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
NODE-303 is a multi-center, open label (OL) study to evaluate the safety of etripamil NS in patients with Paroxysmal Supraventricular Tachycardia (PSVT). Patients will be provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS will be self-applied by the patient, when PSVT symptoms begin. …
- 116 views
- 29 Jul, 2022
- +80 other locations
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period.
- 0 views
- 14 Jul, 2022
- +21 other locations
PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA (PROTRACT)
The purpose of this study is to assess the strategy in treatment selection using ctDNA fraction as a predictive biomarker to direct treatment decision (ctDNA fraction <2% receives enzalutamide, and ctDNA fraction ≥2% receives docetaxel) versus clinician's choice of enzalutamide or docetaxel, in subjects with metastatic castration-resistant prostate cancer post …
- 0 views
- 25 Jul, 2022
- +3 other locations
- 1
- 2